Emcure Pharmaceuticals Board Approves Merger of Wholly Owned Subsidiaries Zuventus and Emcutix
Emcure Pharmaceuticals Ltd 路 Others (Uncategorized) 路 12 Oct 2026, 3:59 pm
Emcure Pharmaceuticals Board Approves Merger of Wholly Owned Subsidiaries Zuventus and Emcutix Emcure Pharmaceuticals' board approved a draft Composite Scheme of Amalgamation on 12th Oct'26 to merge its wholly owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, into itself. For FY25-26, Zuventus reported revenue of INR 1,040.58 crore (net worth INR 871.46 crore), Emcutix posted revenue of INR 29.37 crore (net worth INR -13.07 crore), and Emcure generated revenue of INR 5,243.19 crore. Designed to drive operational efficiencies and rationalization, the merger involves no cash outlay or new share issuance, leaving Emcure's shareholding unchanged, subject to NCLT Mumbai approval.
Original exchange filing (PDF)
More announcements from Emcure Pharmaceuticals Ltd
- Intimation of Cancellation of schedule of Analyst / Investor Meeting(s) scheduled on November 16, 2026 路 15 Nov 2026
- Transcript of Earnings Call - Q2 FY27 held on Tuesday, November 03, 2026 at 4:00 p.m. (IST) 路 06 Nov 2026
- Intimation of schedule of Analyst/Investor Meeting dated Monday, November 16, 2026 路 06 Nov 2026
- Intimation of schedule of Analyst/Investor Meeting on Monday, November 16, 2026 路 06 Nov 2026
- Audio recording of Earnings Call - Q2 FY27 路 04 Nov 2026
- Presentation on Unaudited Financial Results for the quarter ended September 30, 2026 路 03 Nov 2026
- Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026 路 03 Nov 2026
- Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 03 Nov 2026
